Business
Lexicon Pharmaceuticals Announces Two Presentations at the American College of Cardiology’s 70th Annual Scientific Session
THE WOODLANDS, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today there will be two virtual presentations
About this update from Lexicon Pharmaceuticals, Inc.
[{"type":"text","content":"THE WOODLANDS, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today there will be two virtual presentations highlighting sotagliflozin during the American College of Cardiology’s 70th Annual Scientific Session (ACC.21) being held May 15, 2021 through May 17, 2021: Sunday, May 16, 2021, 10:45 am ET; Session 902: “Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review” “Sotagliflozin Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the SOLOIST-WHF Trial” (10:57 am-11:07 am ET). Presented by Michael Szarek, Ph.D. Monday, May 17, 2021, 8:00 am ET; Session 410: “Late-Breaking Clinical Trials IV” “Benefits of Sodium Glucose Co-transporter-1/2 Inhibition with Sotagliflozin Across the Full Spectrum of Ejection Fraction, Including Heart Failure with Preserved Ejection Fraction” (8:00 am-8:10 am ET). Presented by Deepak Bhatt, M.D., M.P.H. About Sotagliflozin Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2). SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney. Sotagliflozin is approved in the European Union (EU) for use as an adjunct to insulin therapy to improve blood sugar (glycemic) control in adults with type 1 diabetes with a body mass index ≥ 27 kg/m2, who could not achieve adequate glycemic control despite optimal insulin therapy, but has not yet been commercially launched. About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure,...